MRI Biomarker for Pulmonary Arterial Hypertension
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 20 (estimated)
- Sponsor
- Bastiaan Driehuys · Other
This trial is looking for people with pulmonary arterial hypertension (PAH). Participants will have MRI scans and other assessments to help understand how their condition changes and responds to treatment.
You may be able to join if
- I am between 18 and 75 years old
- I have been diagnosed with pulmonary arterial hypertension
- I have functional class 2 or 3 as defined by WHO
- My mean pulmonary artery pressure is over 20 mmHg
- My pulmonary capillary wedge pressure is 15 mmHg or less
- My pulmonary vascular resistance is over 2 Wood Units
- I have no other cause for my PAH
- I have a diagnosis of connective tissue disease
You may not be able to join if
- I have pulmonary hypertension from a cause other than idiopathic PAH or connective tissue disease
- I have a condition that prevents me from having MRI scans
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).
Loading trial locations…